What Hailey Bieber has actually said about peptides
The searchable answer first. In her Interview Magazine cover story, "Nobody Says No to Hailey Bieber", published in spring/summer 2026, she said: "I love peptides. That is the base of all of Rhode's skincare. When we launched it, we launched everything with peptides in it, it's like our biggest ingredient in most of our stuff. I think peptides are really amazing. I think there are certain peptides you can take that are really good for hair, skin, and nails, like GHK-Cu, which is the copper peptide, something I take. And then I take these really good hair gummies that are peptides. I've taken immunity peptides before, which I think really worked." A few lines on: "There's one called BPC-157 that you can take orally. It's really good for the gut, muscle repair, and recovery." She added that some peptides are injected, some are oral, and they do not all work the same way.
Parse that carefully. She named two compounds: GHK-Cu, which she says she takes, and BPC-157, which she describes with the pronoun "you" and never quite says she uses. She named two categories without a product, "immunity peptides" in the past tense and "hair gummies" in the present, and she named her own company.
She did not say whether she takes GHK-Cu by injection or by mouth; "something I take", set apart from the topical Rhode products, points to a systemic route and no further. The Hollywood Reporter and an April 2026 ELLE roundup later filed her under celebrities injecting copper and discussing peptide injections, but the needle is the reporters' inference, not her word. She gave no dose, schedule or source, and we will not fill the gaps for her.
What she did not name, and what those phrases mean in the market
When a longevity clinic says "immunity peptide", the compound it almost always means is thymosin alpha-1, a 28-residue thymic peptide sold abroad as thymalfasin. That is a statement about the market's vocabulary, not about Hailey Bieber, who did not name it. If that is what she took, it is the outlier on her list, because it is a real drug somewhere: approved in more than thirty countries for chronic hepatitis B and C and as a vaccine adjuvant, with randomised trials in hepatitis and sepsis.
The caveats are real. Much of the positive data comes from trial regions with different oversight, the sepsis results are mixed, Western regulators have not been persuaded, and it is unapproved in the United States. The evidence covers defined patients with defined infections, not a healthy person hoping for fewer colds, and immune stimulation is contraindicated in active autoimmune disease and after transplant.
"Hair gummies that are peptides" is a different animal. A gummy is a food supplement under DSHEA, and "peptides" on a gummy label nearly always means hydrolysed collagen, digested like any dietary protein. The oral collagen literature has a few small supplier-funded randomised trials on skin hydration; for hair it is thin. She did not name the brand, so neither will we.
What is actually in Rhode's Peptide Glazing Fluid?
Rhode is her company, so her enthusiasm for peptides is also a commercial position, and the fair test is the label. According to INCIDecoder's breakdown of the Peptide Glazing Fluid, the peptide is acetyl hexapeptide-8, better known as argireline, estimated from its position in the ingredient order at somewhere between five hundredths and fifteen hundredths of a percent, alongside niacinamide, marula oil and sodium hyaluronate. That is a well-made hydrating serum with a little of one cosmetic peptide in it. There is no copper peptide on the list.
Argireline is a six-residue fragment built to mimic the N-terminus of SNAP-25, one of the proteins that assemble into the SNARE complex a nerve ending needs to release acetylcholine. Botulinum toxin cleaves SNAP-25 outright; argireline competes for a place in the complex and modestly dampens the signal. Hence the shorthand "topical Botox", and hence why it misleads: a competitor for a binding site and an enzyme that destroys the target are not the same intervention.
The human data is real, small and supplier-flavoured. The ingredient maker's original study applied a ten percent emulsion around the eyes of ten women for a month and reported wrinkle depth down by roughly a quarter on silicone-replica profilometry; a 2013 randomised, placebo-controlled study in Chinese subjects, also at ten percent, reported a measurable reduction over four weeks, and the better work uses split-face designs. The studies used ten percent; the estimate for the glazing fluid is on the order of a tenth of that. Whether a hexapeptide crosses the stratum corneum in meaningful quantity at any concentration remains the standing question.
How argireline compares with Matrixyl and copper tripeptide-1
This is a category with one evidence profile. The best-supported topical cosmetic peptide is probably palmitoyl pentapeptide-4, sold as Matrixyl: a fragment of type I collagen with a palmitic acid tail so it partitions into the barrier, signalling fibroblasts to make more matrix. Its twelve-week double-blind split-face trial against vehicle in around ninety women, showing modest gains in wrinkle depth and roughness, is roughly the ceiling of what any cosmetic peptide has demonstrated. Copper tripeptide-1, GHK-Cu as a cosmetic ingredient, is a third mechanism: a matrikine, a fragment of damaged collagen that tells fibroblasts to rebuild, carrying a copper ion it delivers to cells.
Across all three the pattern is identical: small, short, mostly supplier-funded studies, instrumented endpoints, and effect sizes that reach significance in a few dozen subjects and land well below a prescription retinoid. None of it is nothing. It is also the most modest claim in her interview, and the only one with a controlled human study behind it in the form actually used. A cosmetic may claim to improve appearance; one that says it heals or regenerates has made a drug claim, which is why this category talks about glow rather than repair.
GHK-Cu: the copper peptide she takes, and where its evidence lives
GHK-Cu is glycyl-L-histidyl-L-lysine, a tripeptide of roughly 340 daltons isolated from human plasma in 1973, bound to a copper(II) ion. Plasma GHK falls by roughly sixty percent between twenty and sixty, which is the origin of the restoration logic behind systemic use. In cultured dermal fibroblasts the complex increases synthesis of type I collagen, glycosaminoglycans and proteoglycans while modulating matrix metalloproteinases, more remodelling than bulk deposition. In animal wounds it is angiogenic and speeds closure.
Every controlled human result comes from putting it on skin. Vehicle-controlled facial and eye cream studies in photoaged skin in the early 2000s, mostly reported as conference abstracts, found small effects on graded fine lines and instrumented skin density. A 1994 controlled trial in diabetic neuropathic foot ulcers reported improved closure against vehicle, the strongest human endpoint it has, though it never became an approved wound product. That stronger result comes from skin that is already open, which is exactly why it does not transfer to an intact face, let alone to a syringe or a capsule.
There is no controlled human trial of injected or oral GHK-Cu for any purpose: no registered study, no pharmacokinetics, no approved product anywhere. What supports the practice is a chain of inference: the peptide does interesting things to fibroblasts in a dish, plasma levels fall with age, so restoring them should reproduce the dish. Plasma GHK sits inside a buffered copper-ligand exchange system, a small hydrophilic peptide should clear quickly, and nobody has shown that raising it moves a measured tissue endpoint in a person. "Hair, skin, and nails" is a topical marketing sentence carried across a route it was never studied on.
The copper question and the "copper uglies"
About a sixth of the complex by mass is elemental copper, and the route changes that question. Copper is regulated at intestinal absorption and then in the liver: a cream barely engages that system because so little crosses, a capsule engages it, an injection bypasses it. The adult requirement is around 900 micrograms a day and the North American tolerable upper intake level is 10 milligrams a day, but both are oral figures and neither transfers to a needle. The only clinical precedent for injecting a copper complex is copper histidinate in Menkes disease, an inherited deficiency treated under specialist monitoring, which argues the point rather than against it. Chronic copper excess is hepatotoxic and neurotoxic, and copper is contraindicated in Wilson disease.
That is the background to the reporting that followed her interview. The Hollywood Reporter's 2026 piece on celebrities injecting copper quoted physicians warning of copper toxicity with overdose and immune reactions to the peptide, reported grey-market vials found to contain arsenic and lead, and named a skin reaction some users describe: the "copper uglies". NPR followed on 7 September 2026 with a headline that said it plainly: the trend had gone from creams to injections ahead of the science.
Two things need saying. None of it is about Hailey Bieber's own skin; she has described no side effect and we attribute none to her. And "copper uglies" is a nickname, not a diagnosis. No published case series characterises it, so whether it is a copper effect, an immune response, a contaminant in a vial never made for injection, or a technique problem is unknown. That is not reassurance. It is the finding.
Oral BPC-157: what "you can take it orally" actually changes
BPC-157 is a synthetic fifteen-residue peptide described as a fragment of a protective protein said to occur in gastric juice. The rodent literature is large and consistent across tendon, ligament, muscle, bone, nerve and gut injury models, and it comes overwhelmingly from one Zagreb-based group over three decades. The proposed mechanisms are VEGF receptor 2 signalling, nitric oxide pathways and fibroblast outgrowth. All of it is animal and in-vitro work, much of it reported without blinding or randomisation.
The human record is short enough to state whole. There is no published randomised, placebo-controlled trial of BPC-157 in humans for any indication by any route. The only programme that reached the clinic was an oral formulation, coded PL 14736, taken into early testing for inflammatory bowel disease around two decades ago; tolerability was reported and the efficacy results never appeared in the peer-reviewed literature. Since then the human evidence amounts to a handful of small uncontrolled pilot studies from one US group, including a 2025 intravenous safety pilot in a couple of healthy adults. Human pharmacokinetics by any route have never been published.
So what does "orally" change? Less than the sentence implies. Claimed stability in gastric acid is the basis for oral use and the rodent work includes it, but an unmodified linear fifteen-residue peptide is precisely what the gut is built to dismantle, and no one has measured how much reaches a person's bloodstream. "Good for the gut" is the one use where an oral peptide can plausibly act on the tissue it touches, and it is the indication the FDA's committee weighed in July. "Muscle repair and recovery" by mouth requires systemic absorption never demonstrated in humans. And the theoretical worry travels with the mechanism: new vessels help tendons and also feed tumours.
The regulatory record: the 2023 ban, the April 2026 reversal and the July 2026 vote
In September 2023 the FDA placed nineteen substances, BPC-157 and GHK-Cu among them alongside TB-500, CJC-1295, ipamorelin and KPV, in Category 2 of its 503A bulk-substances review, the category for substances that raise significant safety risks. That barred pharmacy compounding of both compounds she named, on the basis not of demonstrated harm but of an unfilled evidence file: no adequate human pharmacokinetics, unresolved immunogenicity questions, no chronic-exposure assessment. Pentadeca arginate, the same peptide as an arginate salt with no studies of its own, soon appeared as the market's "compliant" substitute.
The politics then moved faster than the science. On 27 February 2026 Robert F. Kennedy Jr., the health secretary, told Joe Rogan he was "a big fan of peptides" and would restore access to around fourteen of them; on 15 April the FDA moved twelve peptides out of Category 2, not into Category 1 but into a limbo between, and announced advisory meetings. On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee, under docket FDA-2025-N-6895, voted 8 to 6 with one abstention in favour of compounding BPC-157 for a single proposed indication: ulcerative colitis. Five other peptides drew similarly narrow favourable votes; one was rejected.
Read the fine print. The FDA's own career scientists told the committee they lacked the evidence to assess safety or effectiveness, and a core concern was that none of these peptides has a universally accepted chemical definition, so identity, quality and batch comparability are unclear. The vote is non-binding; Category 1 placement requires notice-and-comment rulemaking, realistically eight to twelve months, which lands in 2027, and a second meeting on five more peptides is due before the end of February 2027. GHK-Cu was not among the compounds voted on. Neither compound she named is approved for anything, and BPC-157 has been prohibited in sport since 2022.
Once the famous name comes off the vial
Strip her name away and rank what remains. Best supported, in the form actually used: the topical cosmetic peptides, argireline in her own product and palmitoyl pentapeptide-4 and copper tripeptide-1 around it, with small controlled studies, modest instrumented effects and lawful cosmetic status. Next, if that is what her immunity peptide was, thymosin alpha-1: a genuine drug, approved abroad, unapproved here. Then a long drop. Systemic GHK-Cu: a mechanism borrowed from the route it was studied on, no human data, plus a copper question. Oral BPC-157: an enormous rodent literature, one abandoned human programme, no trial by any route.
The inversion is the story. The compound with the best data is the least glamorous, a subtle change in wrinkle depth from a serum over a month. The compounds that drive the headlines, the copper injections and the oral healing peptide, are the ones where nobody has run the study. A testimonial from someone photographed for a living, whose company sells peptides, cannot close that gap, and to her credit she did not claim it could.
Then there is the vial. Neither GHK-Cu nor BPC-157 is manufactured for human use by anyone regulated to do it. What circulates is research-use-only powder, a label meaning the seller makes no representation that the contents are sterile, correctly identified or accurately quantified; the arsenic and lead in the Hollywood Reporter's account are what that label permits. Whatever these peptides do in people, it is not the pharmacology of an unidentified powder, and it is not something a magazine quote can settle.